BNET -- Genentech CEO Arthur Levinson gets no special benefits for agreeing to sell his company to Roche for $95 a share, according to the company’s most recently filed proxy statement.
BNET -- Genentech CEO Arthur Levinson gets no special benefits for agreeing to sell his company to Roche for $95 a share, according to the company’s most recently filed proxy statement.